Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout. 2019
Times Cited: 2
Times Cited: 2
Times Cited
Times Co-cited
Similarity
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
100
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
100
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
50
Clinical features and therapeutic perspectives on hypertension in diabetics.
Shigehiro Katayama, Masako Hatano, Masashi Issiki. Hypertens. Res. 2018
Shigehiro Katayama, Masako Hatano, Masashi Issiki. Hypertens. Res. 2018
50
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
50
Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus.
K Nørgaard, B Feldt-Rasmussen, K Borch-Johnsen, H Saelan, T Deckert. Diabetologia 1990
K Nørgaard, B Feldt-Rasmussen, K Borch-Johnsen, H Saelan, T Deckert. Diabetologia 1990
50
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press. 2016
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press. 2016
50
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
50
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
50
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
50
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
Colleen Majewski, George L Bakris. Diabetes Care 2015
Colleen Majewski, George L Bakris. Diabetes Care 2015
50
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
50
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Alvaro Garcia-Ropero, Juan J Badimon, Carlos G Santos-Gallego. Expert Opin Drug Metab Toxicol 2018
Alvaro Garcia-Ropero, Juan J Badimon, Carlos G Santos-Gallego. Expert Opin Drug Metab Toxicol 2018
50
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mohsen Mazidi, Peyman Rezaie, Hong-Kai Gao, Andre Pascal Kengne. J Am Heart Assoc 2017
Mohsen Mazidi, Peyman Rezaie, Hong-Kai Gao, Andre Pascal Kengne. J Am Heart Assoc 2017
50
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
L Thomas, R Grempler, M Eckhardt, F Himmelsbach, A Sauer, T Klein, P Eickelmann, M Mark. Diabetes Obes Metab 2012
L Thomas, R Grempler, M Eckhardt, F Himmelsbach, A Sauer, T Klein, P Eickelmann, M Mark. Diabetes Obes Metab 2012
50
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim,[...]. PLoS ONE 2016
Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim,[...]. PLoS ONE 2016
50
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
50
Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension.
Robert J Huggett, Eleanor M Scott, Stephen G Gilbey, John B Stoker, Alan F Mackintosh, David A S G Mary. Circulation 2003
Robert J Huggett, Eleanor M Scott, Stephen G Gilbey, John B Stoker, Alan F Mackintosh, David A S G Mary. Circulation 2003
50
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Akiko Sarashina, Kazuki Koiwai, Leo J Seman, Norio Yamamura, Atsushi Taniguchi, Takahiro Negishi, Shogo Sesoko, Hans J Woerle, Klaus A Dugi. Drug Metab. Pharmacokinet. 2013
Akiko Sarashina, Kazuki Koiwai, Leo J Seman, Norio Yamamura, Atsushi Taniguchi, Takahiro Negishi, Shogo Sesoko, Hans J Woerle, Klaus A Dugi. Drug Metab. Pharmacokinet. 2013
50
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
Michael Pfeifer, Raymond R Townsend, Michael J Davies, Ujjwala Vijapurkar, Jimmy Ren. Cardiovasc Diabetol 2017
Michael Pfeifer, Raymond R Townsend, Michael J Davies, Ujjwala Vijapurkar, Jimmy Ren. Cardiovasc Diabetol 2017
50
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. BMC Pharmacol Toxicol 2017
Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. BMC Pharmacol Toxicol 2017
50
A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.
Gita Chawla, Krishna Kr Chaudhary. Diabetes Metab Syndr 2019
Gita Chawla, Krishna Kr Chaudhary. Diabetes Metab Syndr 2019
50
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
50
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
50
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
Tim Heise, Leo Seman, Sreeraj Macha, Peter Jones, Alexandra Marquart, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. 2013
Tim Heise, Leo Seman, Sreeraj Macha, Peter Jones, Alexandra Marquart, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. 2013
50
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
50
Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Sreeraj Macha, Arvid Jungnik, Kathrin Hohl, Dagmar Hobson, Afshin Salsali, Hans J Woerle. Int J Clin Pharmacol Ther 2013
Sreeraj Macha, Arvid Jungnik, Kathrin Hohl, Dagmar Hobson, Afshin Salsali, Hans J Woerle. Int J Clin Pharmacol Ther 2013
50
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Tobias Brand, Sreeraj Macha, Michaela Mattheus, Sabine Pinnetti, Hans J Woerle. Adv Ther 2012
Tobias Brand, Sreeraj Macha, Michaela Mattheus, Sabine Pinnetti, Hans J Woerle. Adv Ther 2012
50
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
50
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.
L M Ruilope, A Salvetti, K Jamerson, L Hansson, I Warnold, H Wedel, A Zanchetti. J. Am. Soc. Nephrol. 2001
L M Ruilope, A Salvetti, K Jamerson, L Hansson, I Warnold, H Wedel, A Zanchetti. J. Am. Soc. Nephrol. 2001
50
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
50
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
50
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int. 2018
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int. 2018
50
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers. Adv Ther 2017
Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers. Adv Ther 2017
50
Hypertension management in patients with diabetes: the need for more aggressive therapy.
Dan R Berlowitz, Arlene S Ash, Elaine C Hickey, Mark Glickman, Robert Friedman, Boris Kader. Diabetes Care 2003
Dan R Berlowitz, Arlene S Ash, Elaine C Hickey, Mark Glickman, Robert Friedman, Boris Kader. Diabetes Care 2003
50
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr. Rev. 2011
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr. Rev. 2011
50
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
50
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Motoaki Sano. J Cardiol 2018
Motoaki Sano. J Cardiol 2018
50
Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.
Ann D Colosia, Roberto Palencia, Shahnaz Khan. 2013
Ann D Colosia, Roberto Palencia, Shahnaz Khan. 2013
50
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.
Bryan Williams, Neil R Poulter, Morris J Brown, Mark Davis, Gordon T McInnes, John F Potter, Peter S Sever, Simon McG Thom. BMJ 2004
Bryan Williams, Neil R Poulter, Morris J Brown, Mark Davis, Gordon T McInnes, John F Potter, Peter S Sever, Simon McG Thom. BMJ 2004
50
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
I M Stratton, C A Cull, A I Adler, D R Matthews, H A W Neil, R R Holman. Diabetologia 2006
I M Stratton, C A Cull, A I Adler, D R Matthews, H A W Neil, R R Holman. Diabetologia 2006
50
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
50
Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.
F Collado-Mesa, H M Colhoun, L K Stevens, J Boavida, J B Ferriss, B Karamanos, P Kempler, G Michel, G Roglic, J H Fuller. Diabet. Med. 1999
F Collado-Mesa, H M Colhoun, L K Stevens, J Boavida, J B Ferriss, B Karamanos, P Kempler, G Michel, G Roglic, J H Fuller. Diabet. Med. 1999
50
Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population.
David M Maahs, Gregory L Kinney, Paul Wadwa, Janet K Snell-Bergeon, Dana Dabelea, John Hokanson, James Ehrlich, Satish Garg, Robert H Eckel, Marian J Rewers. Diabetes Care 2005
David M Maahs, Gregory L Kinney, Paul Wadwa, Janet K Snell-Bergeon, Dana Dabelea, John Hokanson, James Ehrlich, Satish Garg, Robert H Eckel, Marian J Rewers. Diabetes Care 2005
50
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
L Hansson, A Zanchetti, S G Carruthers, B Dahlöf, D Elmfeldt, S Julius, J Ménard, K H Rahn, H Wedel, S Westerling. Lancet 1998
L Hansson, A Zanchetti, S G Carruthers, B Dahlöf, D Elmfeldt, S Julius, J Ménard, K H Rahn, H Wedel, S Westerling. Lancet 1998
50
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Giuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, Cordula Zeller, Ludwin Ley, Hans J Woerle, Uli C Broedl, Odd Erik Johansen. Hypertension 2016
Giuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, Cordula Zeller, Ludwin Ley, Hans J Woerle, Uli C Broedl, Odd Erik Johansen. Hypertension 2016
50
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
50
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma, Ankit Garg, Andrew T Yan, Anup K Gupta, Mohammed Al-Omran, Andre Sabongui, Hwee Teoh, C David Mazer, Kim A Connelly. Diabetes Care 2016
Subodh Verma, Ankit Garg, Andrew T Yan, Anup K Gupta, Mohammed Al-Omran, Andre Sabongui, Hwee Teoh, C David Mazer, Kim A Connelly. Diabetes Care 2016
50
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.